The Artificial Intelligence Act (EU 2024/1689) Whitepaper: Key Obligations, Risks, and Compliance

REPHINE SPEECH MARKS OPEN MEDICALDEVICES

The AI Act sets a global precedent for responsible AI development—balancing innovation with accountability and ensuring AI technologies uphold safety, transparency, and fundamental rights

REPHINE SPEECH MARKS CLOSE MEDICALDEVICES

About this Whitepaper

The Artificial Intelligence Act (Regulation (EU) 2024/1689) is the European Union’s first-ever legislation to comprehensively regulate AI systems. It establishes a risk-based framework to ensure AI technologies are developed and deployed responsibly, balancing innovation with accountability.

This whitepaper provides an essential overview of the AI Act, helping businesses, developers, and public authorities understand the law’s key requirements, who it applies to, and how to prepare for compliance.

Discover the classification of AI systems, specific obligations for high-risk and general-purpose AI models, enforcement mechanisms, penalties, and the upcoming implementation timelines.

Stay ahead of the curve and equip yourself with the knowledge needed to navigate AI regulation confidently.

 

Key Topics Covered

  • What the Artificial Intelligence Act is and why it is needed
  • Who must comply: providers, deployers, importers, distributors, authorised representatives
  • Key definitions: AI systems, systemic risk, general-purpose AI models
  • Risk-based classification of AI systems: Unacceptable, High, Limited, and Minimal risk
  • Detailed obligations for high-risk AI systems, including quality management, transparency, human oversight, and cybersecurity
  • Additional requirements for General-Purpose AI Models with systemic risk
  • Penalties for non-compliance, including fines up to €35 million
  • Practical steps businesses and developers should take now to prepare
  • Important deadlines and the AI Act’s implementation timeline

Learn about AI system risk classifications, compliance obligations, penalties, and timelines and stay ahead of EU AI regulations.

Download your AI Act Compliance Whitepaper

 

Hero Image AI Act WP MedTech

Who this is for

This whitepaper is designed for:

    • AI system developers and providers launching solutions within the EU

    • Organisations deploying AI technologies in operations or services

    • Medical device manufacturers integrating AI into their products

    • Compliance, legal, and regulatory professionals overseeing AI governance

    • Public sector bodies and private organisations using AI in decision-making

    • Anyone seeking to understand and implement the AI Act’s requirements

View our other resources and company news

Ensuring Compliance and Data Integrity in Pharmacovigilan General

Practical compliance and inspection readiness for UK pharmaceutical quality systems

Explore how UK pharmaceutical and biotech organisations can stay prepared for MHRA, EMA and FDA inspections. This session provides expert guidance on inspection trends, compliance ...
Read More
BANNER Practical Guide to Post Market Surveillance PMS under EU MDR IVDR CSV

Practical Guide to the EMA’s Draft EU GMP Revisions

The EU’s new Product Liability Directive (2024/2853) changes who can be held liable and what damages can be claimed. From software and data loss to ...
Read More
BANNER Practical Guide to Post Market Surveillance PMS under EU MDR IVDR Guide

Practical Guide to Post-Market Surveillance (PMS) under EU MDR/IVDR

The EU’s new Product Liability Directive (2024/2853) changes who can be held liable and what damages can be claimed. From software and data loss to ...
Read More
GMP Raising the bar Blog series Header image May 25 Blog

AI for Pharmaceutical SOPs: Transforming Quality Management and Compliance

Rephine helps pharmaceutical and biotech companies transition to digital QMS platforms like Veeva Vault, MasterControl, or TrackWise. From vendor-neutral selection to full GxP-compliant validation and ...
Read More
Ensuring Compliance and Data Integrity in Pharmacovigilan CAPA

Strengthening CAPA & Exceptions Management

Learn how Rephine’s tailored GxP training helped a pharmaceutical manufacturer strengthen CAPA effectiveness, improve compliance, and boost team confidence.
Read More
GMP Raising the bar Blog series Header image May 25 Blog

EU GMP Annex 1 vs FDA Aseptic Guide: Bridging Compliance

EU and U.S. regulators share the same sterility assurance goals, but their approaches differ. Learn how to align Annex 1 and FDA guidance to streamline ...
Read More
GMP Raising the bar Blog series Header image May 25 Blog

GMP & GDP: Ensuring Quality in Drug Storage and Transport

Storage and transport aren’t just logistics — they’re critical GMP processes. Discover how USP helps pharma companies manage risk and maintain quality across global ...
Read More
GMP Raising the bar Blog series Header image May 25 Blog

Blockchain for GMP Documentation: Hype or Future Reality?

Blockchain promises immutability, traceability, and transparency for GMP documentation. But is it a compliance game-changer — or just hype?
Read More
Medical Device Guide

Is Your Insurance Policy Ready for the New EU Product Liability Directive?

The EU’s new Product Liability Directive (2024/2853) changes who can be held liable and what damages can be claimed. From software and data loss to ...
Read More
Contact Us

Strengthen Your Assurance Journey

GMP Chapter 22 Adapting to Hybrid Documentation Standards